Recent advances in understanding antiphospholipid syndrome

F1000Research

Volumn 5, Issue , 2016, Pages

  Bertolaccini, Maria Laura ^a   Sanna, Giovanni ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antiphospholipid syndrome; APS; Hughes Syndrome

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; DISEASE CLASSIFICATION; HETEROZYGOTE; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PROTEIN DOMAIN; REVIEW; RISK FACTOR; SCORING SYSTEM; THROMBOSIS;

EID: 85010888186     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.9717.1     Document Type: Review

References (93)

1. Miyakis S Lockshin MD Atsumi T: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. 16420554 10.1111/j.1538-7836.2006.01753.x
2. Hughes GR: Hughes' syndrome: the antiphospholipid syndrome. A historical view. Lupus. 1998;7(Suppl 2):S1-4. 9814662
3. Abreu MM Danowski A Wahl DG: The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401-14. 25641203 10.1016/j.autrev.2015.01.002
4. Wilson WA Gharavi AE Koike T: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309-11. 10403256 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
5. Galli M Luciani D Bertolini G: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827-32. 12393574 10.1182/blood-2002-02-0441
6. Horbach DA van Oort E Donders RC: Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost. 1996;76(6):916-24. 8972011
7. Wahl DG Guillemin F de Maistre E: Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis. Lupus. 1997;6(5):467-73. 9229367 10.1177/096120339700600510
8. Bertolaccini ML Amengual O Andreoli L: 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014;13(9):917-30. 24824074 10.1016/j.autrev.2014.05.001
9. Bertolaccini ML Gomez S Pareja JF: Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis. 2005;64(11):1639-43. 15817655 10.1136/ard.2005.035824 1755259
10. McNeil HP Simpson RJ Chesterman CN: Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87(11):4120-4. 2349221 10.1073/pnas.87.11.4120 54059
11. Miyakis S Giannakopoulos B Krilis SA: Beta 2 glycoprotein I--function in health and disease. Thromb Res. 2004;114(5-6):335-46. 15507263 10.1016/j.thromres.2004.07.017
12. Iverson GM Victoria EJ Marquis DM: Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998;95(26):15542-6. 9861005 10.1073/pnas.95.26.15542 28079
13. de Laat B Mertens K de Groot PG: Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol. 2008;4(4):192-9. 18285765 10.1038/ncprheum0740
14. 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105(4):1540-5. 15507529 10.1182/blood-2004-09-3387
15. 2-glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol. 2015;67(8):2196-204. 25939498 10.1002/art.39187
16. 2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7(11):1767-73. 19694946 10.1111/j.1538-7836.2009.03588.x
17. 2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res. 2011;128(6):583-6. 21620443 10.1016/j.thromres.2011.04.021
18. Akhter E Shums Z Norman GL: Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol. 2013;40(3):282-6. 23378459 10.3899/jrheum.120084 3605900
19. Pericleous C Ferreira I Borghi O: Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. PLoS One. 2016;11(6):e0156407. 27253369 10.1371/journal.pone.0156407 4890741
20. Wahezi DM Ilowite NT Wu XX: Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. Lupus. 2013;22(7):702-11. 23690366 10.1177/0961203313490241 4138827
21. 2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile? Ann Rheum Dis. 2011;70(2):380-3. 20971718 10.1136/ard.2010.137281
22. Agostinis C Durigutto P Sblattero D: A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood. 2014;123(22):3478-87. 24642748 10.1182/blood-2013-11-537704
23. 2-glycoprotein I: proof of concept. J Thromb Haemost. 2009;7(5):833-42. 19220729 10.1111/j.1538-7836.2009.03316.x
24. 2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology (Oxford). 2015;54(4):722-7. 25273993 10.1093/rheumatology/keu360 4372675
25. 2-glycoprotein-I Domain-I, attenuate experimental antiphospholipid syndrome. J Autoimmun. 2014;54:72-80. 24972993 10.1016/j.jaut.2014.06.001
26. Chow BK Ting V Tufaro F: Characterization of a novel liver-specific enhancer in the human prothrombin gene. J Biol Chem. 1991;266(28):18927-33. 1918008
27. Sciascia S Sanna G Murru V: Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111(2):354-64. 24172938 10.1160/TH13-06-0509
28. Bertolaccini ML Atsumi T Koike T: Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost. 2005;93(2):289-97. 15711745 10.1160/TH04-06-0382
29. Pengo V Ruffatti A Legnani C: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-42. 19874470 10.1111/j.1538-7836.2009.03674.x
30. Pengo V Biasiolo A Pegoraro C: Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93(6):1147-52. 15968401 10.1160/TH04-12-0839
31. Sciascia S Cosseddu D Montaruli B: Risk Scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2011;70(8):1517-8. 21402561 10.1136/ard.2010.145177
32. Pengo V Ruffatti A Legnani C: Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714-8. 21765019 10.1182/blood-2011-03-340232
33. Sciascia S Murru V Sanna G: Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012;10(12):2512-8. 23025466 10.1111/jth.12014
34. Vega-Ostertag M Liu X Kwan-Ki H: A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol. 2006;135(2):214-9. 16965389 10.1111/j.1365-2141.2006.06283.x
35. Oku K Amengual O Zigon P: Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. Rheumatology (Oxford). 2013;52(10):1775-84. 23878313 10.1093/rheumatology/ket234
36. López-Pedrera C Buendía P Cuadrado MJ: Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum. 2006;54(1):301-11. 16385547 10.1002/art.21549
37. Haj-Yahia S Sherer Y: Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model. Lupus. 2003;12(5):364-9. 12765299 10.1191/0961203303lu370oa
38. Du VX Kelchtermans H de Groot PG: From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: pathogenic mechanisms of the antiphospholipid syndrome. Thromb Res. 2013;132(3):319-26. 23958468 10.1016/j.thromres.2013.07.023
39. Cuadrado MJ López-Pedrera C Khamashta MA: Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum. 1997;40(5):834-41. 9153543 10.1002/art.1780400509
40. Amengual O Atsumi T Khamashta MA: The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost. 1998;79(2):276-81. 9493575
41. Pierangeli SS Girardi G Vega-Ostertag M: Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005;52(7):2120-4. 15986360 10.1002/art.21157
42. Oku K Atsumi T Bohgaki M: Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2009;68(6):1030-5. 18625630 10.1136/ard.2008.090670
43. Breen KA Seed P Parmar K: Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost. 2012;107(3):423-9. 22234447 10.1160/TH11-08-0554
44. Proulle V Furie RA Merrill-Skoloff G: Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood. 2014;124(4):611-22. 24825863 10.1182/blood-2014-02-554980 4110663
45. Yalavarthi S Gould TJ Rao AN: Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 2015;67(11):2990-3003. 26097119 10.1002/art.39247
46. López-Pedrera C Aguirre MA Buendía P: Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis Rheum. 2010;62(3):869-77. 20131237 10.1002/art.27299
47. Ma K Simantov R Zhang JC: High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem. 2000;275(20):15541-8. 10809787 10.1074/jbc.275.20.15541
48. Zhang J McCrae KR: Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood. 2005;105(5):1964-9. 15471954 10.1182/blood-2004-05-1708
49. Romay-Penabad Z Montiel-Manzano MG Shilagard T: Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009;114(14):3074-83. 19628708 10.1182/blood-2008-11-188698
50. Sorice M Longo A Capozzi A: Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 2007;56(8):2687-97. 17665396 10.1002/art.22802
51. Ramesh S Morrell CN Tarango C: Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via beta2GPI and apoER2. J Clin Invest. 2011;121(1):120-31. 21123944 10.1172/JCI39828 3007129
52. Romay-Penabad Z Aguilar-Valenzuela R Urbanus RT: Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood. 2011;117(4):1408-14. 21119114 10.1182/blood-2010-07-299099 3320849
53. Ulrich V Gelber SE Vukelic M: ApoE Receptor 2 Mediation of Trophoblast Dysfunction and Pregnancy Complications Induced by Antiphospholipid Antibodies in Mice. Arthritis Rheumatol. 2016;68(3):730-9. 26474194 10.1002/art.39453 4767551
54. Pennings MT van Lummel M Derksen RH: Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost. 2006;4(8):1680-90. 16879209 10.1111/j.1538-7836.2006.02036.x
55. Moestrup SK Schousboe I Jacobsen C: beta2-glycoprotein-I (apolipoprotein H) and beta2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin. J Clin Invest. 1998;102(5):902-9. 9727058 10.1172/JCI3772 508955
56. Satta N Kruithof EK Fickentscher C: Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood. 2011;117(20):5523-31. 21330474 10.1182/blood-2010-11-316158
57. Alard J Gaillard F Daridon C: TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J Immunol. 2010;185(3):1550-7. 20601596 10.4049/jimmunol.1000526
58. Pierangeli SS Vega-Ostertag ME Raschi E: Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis. 2007;66(10):1327-33. 17261530 10.1136/ard.2006.065037 1994302
59. Shi T Giannakopoulos B Yan X: Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum. 2006;54(8):2558-67. 16868978 10.1002/art.21968
60. Urbanus RT Pennings MT Derksen RH: Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost. 2008;6(8):1405-12. 18485085 10.1111/j.1538-7836.2008.03021.x
61. Sikara MP Routsias JG Samiotaki M: {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood. 2010;115(3):713-23. 19805618 10.1182/blood-2009-03-206367
62. Poulton K Rahman A Giles I: Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review. Semin Arthritis Rheum. 2012;41(5):720-36. 22055541 10.1016/j.semarthrit.2011.09.004
63. Canaud G Bienaimé F Tabarin F: Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371(4):303-12. 25054716 10.1056/NEJMoa1312890
64. de Laat B Eckmann CM van Schagen M: Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis. 2008;19(8):757-64. 19002041 10.1097/MBC.0b013e32830f1b85
65. Galli M Willems GM Rosing J: Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol. 2005;129(2):240-7. 15813852 10.1111/j.1365-2141.2005.05438.x
66. Patterson AM Ford I Graham A: The influence of anti-endothelial/antiphospholipid antibodies on fibrin formation and lysis on endothelial cells. Br J Haematol. 2006;133(3):323-30. 16643435 10.1111/j.1365-2141.2006.05994.x
67. Ieko M Yoshida M Naito S: Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation. Int J Hematol. 2010;91(5):776-83. 20490730 10.1007/s12185-010-0590-0
68. Gombás J Tanka-Salamon A Skopál J: Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins. Blood Coagul Fibrinolysis. 2008;19(1):82-8. 18180621 10.1097/MBC.0b013e3282f38c6f
69. López-Lira F Rosales-León L Martínez VM: The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen. Biochim Biophys Acta. 2006;1764(4):815-23. 16480936 10.1016/j.bbapap.2005.12.020
70. Lean SY Ellery P Ivey L: The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation. Haematologica. 2006;91(10):1360-6. 17018385
71. Liestøl S Sandset PM Jacobsen EM: Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. Br J Haematol. 2007;136(1):131-7. 17092306 10.1111/j.1365-2141.2006.06385.x
72. 2-glycoprotein I on thrombin-mediated factor XIa generation. Arthritis Rheum. 2007;56(2):605-13. 17265495 10.1002/art.22367
73. 2-glycoprotein I autoantibodies. Arthritis Rheum. 2008;58(4):1146-55. 18383370 10.1002/art.23387
74. de Laat B Wu XX van Lummel M: Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood. 2007;109(4):1490-4. 17053060 10.1182/blood-2006-07-030148
75. Rand JH Wu XX Quinn AS: Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010;115(11):2292-9. 19965621 10.1182/blood-2009-04-213520 2844013
76. Hunt BJ Wu XX de Laat B: Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol. 2011;205(5):485.e17-23. 21784397 10.1016/j.ajog.2011.06.019 3205287
77. Wu XX Guller S Rand JH: Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am J Obstet Gynecol. 2011;205(6):576.e7-14. 21871597 10.1016/j.ajog.2011.06.064 3224185
78. 2-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood. 2011;118(10):2774-83. 21757614 10.1182/blood-2011-02-339564
79. Otomo K Atsumi T Amengual O: Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504-12. 21953404 10.1002/art.33340
80. Sciascia S Sanna G Murru V: GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013;52(8):1397-403. 23315788 10.1093/rheumatology/kes388
81. Sciascia S Bertolaccini ML Roccatello D: Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2013;72(1):142-3. 22843492 10.1136/annrheumdis-2012-201985
82. Bertolaccini ML Amengual O Atsumi T: 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011;20(2):191-205. 21303836 10.1177/0961203310397082
83. Sciascia S Cuadrado MJ Sanna G: Prospective validation of the Global AntiPhospholpid Syndrome Score (GAPSS). Arthritis Rheum. 2013;65:S3.
84. Sciascia S Sanna G Murru V: The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford). 2015;54(1):134-8. 25122726 10.1093/rheumatology/keu307
85. Zuily S de Laat B Mohamed S: Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford). 2015;54(11):2071-5. 26163690 10.1093/rheumatology/kev238
86. Oku K Amengual O Bohgaki T: An independent validation of the Global Anti-Phospholipid Syndrome Score in a Japanese cohort of patients with autoimmune diseases. Lupus. 2015;24(7):774-5. 25432782 10.1177/0961203314561284
87. Aggarwal R Ringold S Khanna D: Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67(7):891-7. 25776731 10.1002/acr.22583 4482786
88. Barbhaiya M Erkan D: Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr Rheumatol Rep. 2011;13(1):59-69. 21104348 10.1007/s11926-010-0149-3
89. Shah NM Khamashta MA Atsumi T: Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus. 1998;7(1):3-6. 9493141 10.1191/096120398678919624
90. Girón-González JA García del Río E Rodríguez C: Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31(8):1560-7. 15290736
91. Erkan D Harrison MJ Levy R: Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56(7):2382-91. 17599766 10.1002/art.22663
92. Ruffatti A Del Ross T Ciprian M: Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011;70(6):1083-6. 21285115 10.1136/ard.2010.142042
93. Cuadrado MJ Bertolaccini ML Seed PT: Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford). 2014;53(2):275-84. 24097288 10.1093/rheumatology/ket313